Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients

Real‐life Practice Experts for, HCC (RELPEC) Study Group, and, HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan)

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases